基本信息
浏览量:13
职业迁徙
个人简介
Dr. Xin Ge, PhD is an Associate Professor of Molecular Medicine at University of Texas Health Science Center at Houston and Kay & Ben Fortson Distinguished Chair in Neurodegenerative Disease Research. Dr. Ge earned his B.S. and M.S. in Chemical and Biochemical Engineering from Tsinghua University in Beijing, China. Afterward, he obtained his Ph.D. from McMaster University in Hamilton, Canada in the laboratory of Dr. Carlos Filipe. He then carried out postdoctoral research at University of Texas at Austin with Dr. George Georgiou. In the Summer of 2011, Dr. Ge joined the faculty of University of California Riverside in the Department of Chemical and Environmental Engineering, and in July 2021 he moved his lab to the University of Texas Health Science Center at Houston and became a member of the Institute of Molecular Medicine and Texas Therapeutics Institute.
Dr. Ge was trained as a biochemical engineer, and his PhD and postdoc works were in protein science and engineering. Since independence, his lab focuses on developing biologics, such as monoclonal antibodies (mAbs), T-cell receptors (TCRs) and therapeutic enzymes. His research group is committed to inventing enabling technologies that facilitate biologics development, which are important but difficult or even impossible with current methods. Bypassing the limits associated with what nature offers, we apply engineering strategies and streamline a set of in vitro approaches including synthetic library construction, structure-aided design, mammalian cell display, functional selection, and repertoire deep sequencing. Combinations of these approaches provide a powerful means for discovery and engineering highly potent biologics relevant to disease diagnosis and treatment.
One exemplary research project is protease inhibitory mAbs. We choose this topic because it is clear that (a) proteases are important drug targets; (b) their compound inhibitors largely failed in clinical trials; and (c) conventional mAb technologies are incompetent for protease inhibition. In the past ten years my lab has been developing a series of novel technologies, i.e. synthetic custom antibody libraries (PNAS 2016) and functional selection/screening (PNAS 2019), and has generated panels of potent and highly specific mAbs inhibiting numerous proteases of biomedical importance. These targets represent major classes of proteases and are associated with various diseases: matrix metalloproteinase (MMP)-14 (metastasis), MMP-9 (neuropathic pain), MMP-12 (atherosclerosis), β-secretase 1 (BACE1, aspartyl protease, Alzheimer’s disease), cathepsin B (cysteine protease, cancer), and Alp2 (serine protease, aspergillosis). We further characterized the inhibition mechanisms of these mAbs and optimized their potency and stability. Our mAbs have shown significant therapeutic efficacy in multiple animal models of cancers, obesity, pain, and stroke.
研究兴趣
论文共 64 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
ANTIBODY THERAPEUTICSno. 3 (2024): 209-220
BIOTECHNOLOGY PROGRESSno. 1 (2024)
Frontiers in bioengineering and biotechnology (2024)
Methods in molecular biology (Clifton, N.J.) (2024): 243-256
CELL REPORTS MEDICINEno. 12 (2023)
The journal of pain/Journal of painno. 4 (2023): 46-46
Pharmacological Research (2023): 106720
PROTEIN SCIENCEno. 7 (2023)
加载更多
作者统计
#Papers: 64
#Citation: 1440
H-Index: 20
G-Index: 37
Sociability: 5
Diversity: 3
Activity: 65
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn